Last reviewed · How we verify

NCT03211026: URIKIT

Urinary Tract Infections in Kidney Transplant Recipients

Status unknown Last updated 14 April 2021
What this trial tests

trial testing No intervention in Kidney Transplantation in 120 participants. Status unknown.

Timeline
4 May 2017
Primary endpoint
4 May 2022
4 May 2024

Quick facts

Lead sponsorPoitiers University Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment120
Start date4 May 2017
Primary completion4 May 2022
Estimated completion4 May 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Poitiers University Hospital

Who can join

18 and older, any sex, with Kidney Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to better estimate the prevalence of urinary tract infections (UTI) in kidney transplant (KIT) recipients, and especially multidrug resistant (MDR) bacteria. KIT recipients have a higher risk of UTI over the 6 first months following the transplantation. Urine culture was done in a city lab or at hospital. Current data on bacteriuria and candiduria lead mostly to hospital data that are incomplete..

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Kidney Transplantation

Currently open trials in the same condition.

Other Poitiers University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03211026.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing